title: Alleviation of asthma-related symptoms by a derivative of L-allo threonine.
abstract: Chronic asthma is characterized by inflammatory cell infiltration and tissue remodeling, leading to subepithelial inflammation. In order to evaluate the anti-asthmatic activity of LX519290, a derivative of L-allo threonine, we performed several in vitro and in vivo anti-asthmatic assays. Using ovalbumin (OVA)-sensitized C57BL/6 mice, the effects of LX519290 on lung inflammation and cytokine expression in the asthmatic animals were analyzed. Treatment with this compound increased IFN-γ and decreased IL-10 mRNA expression. LX519290 potently decreased, not only immune cell infiltration in the lung, but also IL-4 and IL-13 cytokine levels in the serum of OVA-treated mice. The results demonstrated that LX519290 decreased the pathogenesis of chronic airway injury. Evidence from our model of OVA-induced asthma demonstrated that LX519290 inhibits immune cell infiltration, mucus hypersecretion, and inflammatory cytokine production. Collectively, our findings suggest that LX519290 has the potential to ameliorate asthmatic symptoms by treating inflammatory factors in the lung.
authors: Food and Bio-Industry Research Institute, Kyungpook National University, Daegu 702-701, Republic of Korea.
authors: Jin-Chul
authors: JC
authors: Heo
authors: Sang-Han
authors: SH
authors: Lee
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D016207:Cytokines / Q000097:blood / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D007150:Immunohistochemistry; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000633:toxicity; D011014:Pneumonia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D016133:Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D013912:Threonine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D018927:Anti-Asthmatic Agents; D016207:Cytokines; D006834:Hydrazines; C581088:LX519290; D013912:Threonine; D010047:Ovalbumin